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S U M M A R Y
We report the case of a 50-year-old female patient with non-active sarcoidosis and no kind of
immunosuppression, admitted to our hospital because of increasing confusion and focal neurological
deﬁcits. Initially a tumor, herpes encephalitis, or neurosarcoidosis were suspected, but surprisingly
biopsy revealed progressive multifocal leukoencephalopathy, additionally conﬁrmed by JC-positive PCR
in cerebrospinal ﬂuid. Cases of sarcoidosis and progressive multifocal leukoencephalopathy have been
reported before. This is the ﬁrst case of a patient with no sign of active sarcoidosis and without
immunosuppressive therapy who recovered spontaneously with a follow-up time of nearly 3 years.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Progressive multifocal leukoencephalopathy (PML) is a nor-
mally fatal demyelinating disease of the central nervous system,
caused by human polyomavirus JCV, rarely affecting immunocom-
petent persons. The seroprevalence of JCV is up to 80%; the route of
infection is unknown.1 We report the ﬁrst case of a patient with
no sign of active sarcoidosis and without immunosuppressive
therapy who recovered spontaneously with a follow-up time of
nearly 3 years.
2. Case report
A 50-year-old woman with speech disturbances and changes
of personality was admitted to our clinic in April 2006 under the
suspicion of a brain tumor. An ambulant computer tomography
of the brain had already revealed a left fronto-parietal hypodense
area. She had a 20-year medical history of sarcoidosis with
pulmonary and joint involvement and had undergone resection
of a basalioma 16 years ago. Immunosuppressive treatment with* Corresponding author. Tel.: +49 511 532 2391; fax: +49 511 532 3115.
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therapy with corticosteroids between 1988 and 1997. Clinical
examination revealed sensory–motor dysphasia, apraxia, sac-
cadic eye movements, and rigor and tremor, especially on the
right side.
Magnetic resonance imaging (MRI) demonstrated cortical and
subcortical hyperintense lesions predominately in the left
hemisphere on a T2-weighted ﬂuid attenuated inversion recovery
(T2-FLAIR) sequence. The fronto-temporal lesion on the left side
included the U-ﬁbers and showedminimal mass effect (Figure 1A).
Diffusion weighted images (DWI) depicted restricted diffusion in
the subcortical frontal white matter (Figure 1B). Gliomatosis
cerebri was suspected and the patient was treated with
dexamethasone for reduction of edema. Thereafter she became
psychotic with hallucinations, anxiety, and aggressive behavior. A
second MRI one week later showed no signiﬁcant differences. The
suspected diagnosis was changed to encephalitis and a lumbar
puncture was performed. Cerebrospinal ﬂuid (CSF) was normal
with regard to cell count, cell differential, total protein concentra-
tion, and albumin quotient, but showed high intrathecal IgG (60%)
and IgM (79%) synthesis and positive oligoclonal bands. Investiga-
tion of the CSF for herpes simplex virus (HSV) type 1 found PCR to
be borderline positive, though not quantiﬁable, and no intrathecal
antibody production against HSV, with an antigen antibody indexses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Magnetic resonance imaging (MRI) ﬁndings: (A) Early after admission T2-weighted ﬂuid attenuated inversion recovery (FLAIR) showed cortical and subcortical
hyperintense lesions in the left frontal lobe with minimal mass effect involving the U-ﬁbers. (B) Diffusion weighted imaging (DWI) showed restricted diffusion in the
subcortical white matter at the same level as in (A) with reduced apparent diffusion coefﬁcient (ADC) values. (C) A follow-up MRI after one month depicted a cortical
hyperintense cortex and subcortical edema involving the basal ganglia on T1-weighted images without contrast media. (D)With contrast media a juxtacortical enhancement
was noted. (E) T2-weighted FLAIR one year after onset showedmarked substance loss in the involved white matter with residual hyperintense signal consistent with gliosis.
(F) Compared to (C) a marked volume loss of the cortex and subcortical white matter was seen one year after onset of symptoms. The hyperintense signal of the cortex was
reduced.
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encephalitis was assumed and the patient was treated with
acyclovir 10 mg/kg body weight for 14 days. As the patient’s
condition continued to worsen, a second lumbar puncture was
performed 11 days later. A slight pleocytosis with 10  106 cells/l
(82% lymphocytes, 10% eosinophils) was found. Local IgG and IgM
synthesis was still increased at similar levels and oligoclonal bands
were unaltered. Herpes encephalitis was now deﬁnitely excluded
by a normal HSV antibody speciﬁcity index (ASI) and negative PCR,
and neurosarcoidosis was subsequently considered. Tests for HIV[(Figure_2)TD$FIG]
Figure 2. Neuropathological ﬁndings: (A) Necrosis (*) with macrophage inﬁltration and
oligodendrocyteswith abnormal big dark nuclei ( ) (hematoxylin–eosin, originalmagniﬁ
astroglial cells.and viral hepatitis were negative, as were intrathecal AI for
cytomegalovirus, measles, rubella, and varicella zoster virus. A
follow-up MRI four weeks after the ﬁrst one showed hyperintense
cortex in the frontal lobe without signs of hemorrhage or
calciﬁcation on T2*-weighted images (Figure 1C). Cortical and
subcortical contrast enhancement including the U-ﬁbers was
noted (Figure 1D).
A stereotactic brain biopsy was then performed. Histology
revealed inﬂammation with inﬁltration of mainly cytotoxic T-
lymphocytes and demyelination in the cortex and subcortex withmarked gliosis with reactive astrocytes with prominent cytoplasm (b), as well as
cation200). (B) Immunohistochemistrywith positive reaction for SV40-antigen in
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nohistochemical assay was positive for Simian virus 40 (SV40)
(Figure 2B). Antibodies against SV40 show cross-reactivity with
the JC virus (JCV), the agent responsible for PML. After conﬁrmation
of JCV in the CSF by PCR, PML was ﬁnally diagnosed. A blood count
and analysis of lymphocyte subpopulations and CD4/CD8 ratio
(1.67, normal 0.9–1.70)were normal. No signs of progression of the
sarcoidosis could be detected.
Surprisingly the patient improved after the biopsy, while all
medication had been stopped. Aphasia and motor functions
improved and she was completely oriented. Panic and aggression
attacks necessitated temporary treatment with olanzapine. Finally
the patient was discharged to a rehabilitation clinic.
Eight months later the patient developed a pneumonia, which
was treated with antibiotics and for unknown reasons also with
steroids. Thereby hallucinations, agitation, and confusion were
again induced. Cessation of the steroid therapy and commence-
ment of olanzapine quickly restored her former constitution and
she was able to live alone with only minimal assistance. One year
later, after the patient had stopped the olanzapine therapy for
some weeks, yet another psychotic attack occurred in which she
suffered delusions that she would die of thirst and hunger. At this
time MRI showed marked substance loss and hyperintensities
consistent with gliosis predominantly in the subcortical white
matter, including the U-ﬁbers (Figure 1E). The cortex in the
affected areas was thinned and a reduction of the hyperintense
signal on T1-weighted images could be seen. Contrast enhance-
ment was not noted (Figure 1F). A control investigation of the CSF
showed a normal cell count and albumin quotient, but IgG and IgM
were still high (64% and 50%, respectively) with persistent
oligoclonal IgG bands. PCR for JCV-DNA was negative. The patient
stabilized quickly after resumption of the olanzapine medication.
Nearly three years after the onset of symptoms, the patient still
has an organic psycho-syndrome with anxiety, word-ﬁnding
difﬁculties, and a mild resting and intentional tremor of the right
arm. She hasmoved into assisted living accommodation, but needs
only minimal help in daily life.
3. Discussion
The correct diagnosis in our case was delayed because PML was
not included in the differential diagnosis for a patient who was
apparently immunocompetent, and the neuroimaging as well as
the CSF ﬁndings were rather untypical for PML. Sarcoidosis is a
granulomatous disease with manifestation in the intrathoracic
lymph nodes and multiple extrathoracic locations, including the
central nervous system. The exact etiology remains unclear. The
immunological reaction in sarcoidosis is mediated through T-
lymphocytes. In acute sarcoidosis bronchoscopy shows a lympho-
cytic alveolitis, with an increased CD4/CD8 ratio.2 Disturbance of T
lymphocytes may predispose to PML, because JCV-speciﬁc
cytotoxic T lymphocytes seem to protect immunocompetent
people against the development of PML3 and are associated with
a favorable outcome of PML in HIV-infected patients.4
Although opportunistic infections in sarcoidosis are rare,5 the
coincidence of sarcoidosis and PML has been known for decades.6
We found one published case of a patient with sarcoidosis without
immunosuppression and a postmortemdiagnosis of PML.7 Another
case (presented as an abstract) was treated with cidofovir and
recovered in the 4 months of follow-up.8 And in one case the
manifestations of PML led to the diagnosis of sarcoidosis.9 The
patient was also treated with cidofovir, but additionally with
corticosteroids due to sarcoidosis-induced T-lymphocytopenia.
The follow-up time in this case was 2 years. Several cases of PML in
immunosuppressed patients with sarcoidosis have been pub-
lished.10–12 We present the ﬁrst case of a patient with medication-free, inactive sarcoidosis and PML, who improved without any
speciﬁc antiviral treatment, with a follow-up of nearly 3 years. No
similar case with similar clinical symptoms and course of disease
has been described in patients with a history of sarcoidosis, but has
been for example with leukaemia.13
Our patient was treated with acyclovir because of suspected
herpes encephalitis. Acyclovir is used against infections with
viruses of the herpes group; however there are no indications that
it may also be active against JCV.
The patient is now under olanzapine therapy. It has recently
been reported that JCV uses the serotonergic receptor 5HT2A to
infect human glia cells.14 Antipsychotics have been considered to
be useful in PML therapy, with mirtazapine being the most used
drug.15,16 Olanzapine is also an antagonist at the 5HT2A receptor,
17
although not the most potent compared to other neuroleptics. The
blocking of the 5HT2A receptor by olanzapine may prevent a new
eruption of infection in our patient. In our opinion the recurring
psychotic decompensations were not related to new inﬂammatory
activity but to the extensive brain damage with the associated
addition of glucocorticoids and the termination of the antipsy-
chotic therapy .
OnMRI, hyperintense subcortical lesions in the white matter in
a FLAIR sequence, with minor mass effect involving the U-ﬁbers
and the cortex of more than three lobes, are typical ﬁndings of
gliomatosis cerebri.18 However, areas of restricted diffusion in the
white matter unrelated to vascular territories are atypical for
gliomatosis and can be seen in systemic diseases like toxic,
metabolic, or hypertensive encephalopathy.19 An unusual ﬁnding
was the hyperintense signal of the cortex on T1-weighted imaging
(T1w) onemonth after the onset of symptoms. Focal hemorrhage is
an atypical pattern in PML20 and a susceptibility sensitive MRI
sequence (T2*-weighted gradient echo sequence) ruled out even a
minor bleed. The development of a hyperintense cortex in T1w in
the overlaying white matter one month after the diffusion
restriction could be interpreted as cortical damage, similar to
the signs of cortical laminar necrosis. In the case of PML, restricted
diffusion is a sign of an active infection.21
Contrast enhancement of the PML lesions, as was present in the
second MRI, was interpreted as an inﬂammatory reaction, and
supported in this case by the ﬁndings of a cytotoxic T-lymphocyte
inﬁltrate in the biopsy. Such alterations in MRI imaging have
mainly been observed in HIV-infected patients with PML after
initiation of highly active antiretroviral therapy and were
associated with the initial clinical deterioration. Whether this
immune-reconstitution inﬂammatory syndrome inﬂuences out-
come is unclear. A multicenter observation did not reveal an
inﬂuence on mortality,22 and other authors have described a
favorable outcome.3,23,24
In conclusion, PML should be considered in patients with a
history of sarcoidosis and new neurological deﬁcits even if there is
no hint of active sarcoidosis. Contrast enhancement of the PML
lesions in such cases is associated with an increased inﬂammatory
reaction and a potentially favorable outcome. A therapeutic
interventionwith serotonin receptor antagonistsmay be indicated.
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